InsiderClue
← All stocks

BIOCRYST PHARMACEUTICALS INC

BCRX Net buying
CIK 0000882796 #1887 in the set updated 19 Sep 2026
Bought (120 mo)
$2.11M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$30.94M
$1.03M on a plan · $28.10M straight out of an exercise
Sold at will
$1.81M
21 of 114 sales
Net
−$28.83M
+$302.39K against sales at will

By person

28 insiders · 159 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Stonehouse Jon P
Director
$239.00K (2)
$9.66M (7) scheduled
−$9.42M
1,460,419
0.5715%
$13.10M
+97.2%
Sheridan William P
Chief Medical Officer
—
$6.82M (9) scheduled
−$6.82M
37,954
0.0149%
$340.45K
−67.1%
Barnes Alane P
Chief Legal Officer
$56.65K (2)
$5.34M (12) scheduled
−$5.29M
400,703
0.1568%
$3.59M
+321.3%
Hutson Nancy J
Director
$46.40K (2)
$2.17M (4) scheduled
−$2.12M
99,138
0.0388%
$889.27K
+268.9%
ABERCROMBIE GEORGE B
Director
—
$1.66M (8) scheduled
−$1.66M
36,431
0.0143%
$326.79K
+264.3%
STAAB THOMAS R II
Senior Vice President and CFO
—
$1.30M (34) scheduled
−$1.30M
125,176
0.0490%
$1.12M
+0.8%
HEGGIE THERESA
Director
$7.25K (1)
$1.14M (3) scheduled
−$1.13M
80,646
0.0316%
$723.39K
—
Babu Yarlagadda S
Chief Discovery Officer
$36.25K (1)
$1.15M (3) scheduled
−$1.11M
298,541
0.1168%
$2.68M
+167.9%
Doyle Anthony
Chief Financial Officer
$862.53K (3)
$62.13K (1)
+$800.40K
377,867
0.1479%
$3.39M
—
Powell Lynne
Senior VP - CCO
—
$538.73K (19) scheduled
−$538.73K
0
0.0000%
$0.00
−100.0%
Cohen Fred E
Director
—
$294.04K (1) scheduled
−$294.04K
119,410
0.0467%
$1.07M
+4.7%
MILANO VINCENT
Director
$185.18K (2)
—
+$185.18K
109,642
0.0429%
$983.49K
+996.4%
Jones Michael L
Exec. Director, Finance - PAO
—
$156.30K (3) scheduled
−$156.30K
16,653
0.0065%
$149.38K
+1,864%
McKee Amy E
Director
—
$154.64K (2)
−$154.64K
47,821
0.0187%
$428.95K
—
SANDERS MACHELLE
Director
—
$128.60K (3) scheduled
−$128.60K
45,936
0.0180%
$412.05K
—
Galson Steven K
Director
$120.45K (1)
—
+$120.45K
27,794
0.0109%
$249.31K
—
Gayer Charles K
President and CCO
$164.10K (1)
$66.49K (1)
+$97.61K
952,583
0.3728%
$8.54M
+823.1%
LEE KENNETH B JR
Director
$7.25K (1)
$92.10K (1) scheduled
−$84.85K
68,863
0.0269%
$617.70K
+571.7%
Sniecinski Megan
Chief Business Officer
$65.25K (1)
—
+$65.25K
45,000
0.0176%
$403.65K
—
ASELAGE STEVE
Director
$65.06K (4)
—
+$65.06K
72,659
0.0284%
$651.75K
—
LEVIN ALAN G
Director
$50.00K (1)
—
+$50.00K
79,565
0.0311%
$713.70K
—
Thackray Helen M.
Chief R&D Officer
$175.80K (1)
$215.18K (3)
−$39.38K
377,318
0.1477%
$3.38M
—
INGRAM ROBERT ALEXANDER
Director
$29.00K (1)
—
+$29.00K
100,198
0.0392%
$898.78K
+4,018%
Ghias Babar
Chief Financial Officer
—
—
—
268,700
0.1052%
$2.41M
—
Menon Sandeep
Chief R&D Officer
—
—
—
205,150
0.0803%
$1.84M
—
Erck Stanley C
Director
—
—
—
48,333
0.0189%
$433.55K
+20.8%
Frank Steven
Director
—
—
—
36,747
0.0144%
$329.62K
—
Milne Jill C.
Director
—
—
—
33,226
0.0130%
$298.04K
—

Individual transactions

24
Insider
Date
Role
Action
Shares
Price
Amount
LEVIN ALAN G
30 May 2024
Director
Buy
7,861
$6.36
$50.00K
ASELAGE STEVE
24 May 2024
Director
Buy indirect
2,500
$6.40
$16.00K
MILANO VINCENT
20 May 2024
Director
Buy
15,000
$6.25
$93.75K
Hutson Nancy J
20 May 2024
Director
Buy
5,000
$6.38
$31.90K
Thackray Helen M.
14 May 2024
Chief R&D Officer
Buy
30,000
$5.86
$175.80K
Doyle Anthony
14 May 2024
Chief Financial Officer
Buy
36,300
$5.57
$202.19K
Gayer Charles K
13 May 2024
Chief Commercial Officer
Buy
30,000
$5.47
$164.10K
Stonehouse Jon P
13 May 2024
President & CEO
Buy
30,000
$5.55
$166.50K
Barnes Alane P
13 May 2024
Chief Legal Officer
Buy
5,000
$5.53
$27.65K
Galson Steven K
13 May 2024
Director
Buy
21,940
$5.49
$120.45K
MILANO VINCENT
24 Nov 2021
Director
Buy
7,500
$12.19
$91.43K
Doyle Anthony
23 Nov 2021
Chief Financial Officer
Buy
35,258
$12.48
$440.02K
Doyle Anthony
11 Aug 2020
Chief Financial Officer
Buy
54,000
$4.08
$220.32K
ASELAGE STEVE
18 Nov 2019
Director
Buy
15,000
$1.45
$21.75K
Babu Yarlagadda S
18 Nov 2019
Senior VP - Drug Discovery
Buy
25,000
$1.45
$36.25K
Barnes Alane P
18 Nov 2019
Senior VP, Chief Legal Officer
Buy
20,000
$1.45
$29.00K
HEGGIE THERESA
18 Nov 2019
Director
Buy
5,000
$1.45
$7.25K
Hutson Nancy J
18 Nov 2019
Director
Buy
10,000
$1.45
$14.50K
INGRAM ROBERT ALEXANDER
18 Nov 2019
Director
Buy
20,000
$1.45
$29.00K
LEE KENNETH B JR
18 Nov 2019
Director
Buy
5,000
$1.45
$7.25K
Sniecinski Megan
18 Nov 2019
Chief Business Officer
Buy
45,000
$1.45
$65.25K
Stonehouse Jon P
18 Nov 2019
President & CEO
Buy
50,000
$1.45
$72.50K
ASELAGE STEVE
22 May 2019
Director
Buy
3,000
$3.57
$10.71K
ASELAGE STEVE
12 Mar 2019
Director
Buy
2,000
$8.30
$16.60K
Show all 159 transactions →

What was left out

Form 4 filings counted 457
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 86
Sales at will 21
Transactions with no price 0
Shares from compensation/vesting 8,263,448
Sales filed before the plan box existed 15
History held since 6 Sep 2016